NGENF News and Press, NervGen Pharma Corp From 09/22/22

Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Direct...

Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repair Dr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - ...

--News Direct-- Finding the cure to Alzheimer’s has confounded researchers for decades. As a disease, Alzheimer’s is highly complex and has a wide range of symptoms , including sleeplessness, wandering, agitation, anxiety, aggression, restlessness and depressio...

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) -   NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will present a po...

NervGen Pharma press release ( OTCQX:NGENF ): Q2 GAAP EPS of -$0.13. Cash position enhanced by over $22M. For further details see: NervGen Pharma GAAP EPS of -$0.13

Cash position enhanced by over $22 million due to private placement and exercise of warrants and options Dosing in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial ongoing Discussions ongoing with FDA regarding partial clinical hold Update provided on ...

Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - NervGen Pharma Corp., (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, will present the study design for its upcoming Ph...

The independent peer-reviewed study showed improved memory as well as motor and sensory functions in rodents when treatment with NVG-291-R began 7 days after stroke onset There is currently no FDA-approved drug for the repair of damage from a stroke NVG-291, currently in a Pha...

Vancouver, British Columbia--(Newsfile Corp. - July 14, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it has clo...

Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James Guest NervGen will also present at the International Investment Forum ...